What is evident from this study is that IL1 pathway seems to play a pivotal role on the risk of mortality in severe COVID-19 patients, as previously postulated (Attur et al., 2023), and that genetic regulation of these genes could have an impact on the efficacy of Tocilizumab in terms of mortality. The gene discussed is IL1B; the disease is COVID-19.